Interestingly, breast cancer patients harboring nonsynonymous somatic mutations on BCL2L1-HRAS reveals poor survival rate compared to the wild-type status on both BCL2L1 and HRAS (P = 0, log-rank test, S6C Fig). Here, BCL2L1 is linked to breast carcinoma.